Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,583,938 shares of the biopharmaceutical company’s stock after purchasing an additional 88,653 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Pfizer were worth $56,547,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Shine Investment Advisory Services Inc. bought a new stake in Pfizer during the second quarter valued at $102,000. Mckinley Capital Management LLC Delaware bought a new stake in Pfizer during the second quarter valued at $103,000. Herndon Capital Management LLC bought a new position in shares of Pfizer during the 2nd quarter worth about $120,000. Private Vista LLC boosted its position in shares of Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares in the last quarter. Finally, Lipe & Dalton boosted its position in shares of Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 71.41% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down $0.16 on Monday, hitting $36.61. 25,210,000 shares of the stock were exchanged, compared to its average volume of 29,020,000. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. The company has a market cap of $217,930.00, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 2.07 and a beta of 0.91.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.47 earnings per share. sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.71%. The ex-dividend date of this dividend was Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is currently 77.71%.
Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.
A number of equities research analysts recently weighed in on the stock. Sanford C. Bernstein set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Goldman Sachs Group set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. UBS Group set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Finally, Deutsche Bank set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $39.40.
In other news, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. In the last quarter, insiders sold 185,464 shares of company stock worth $6,767,939. Insiders own 0.06% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://ledgergazette.com/2018/03/13/skandinaviska-enskilda-banken-ab-publ-has-56-55-million-stake-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.